Searched for
SEMAGLUTIDE API PRICE
Be stock-specific, look for bargains: Daljeet Kohli on Nifty at 24,000 and top sector picksMarket expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...- Dr Reddy’s launches oral semaglutide in IndiaDr Reddys Laboratories has launched its oral semaglutide biosimilar for type 2 diabetes in India. The drug, Obeda, is available in three ta...
- Weight-loss drug semaglutide set to get cheaper as generic wave builds in IndiaPrices for generic semaglutide, a popular weight-loss drug, are expected to fall by more than half in the coming months. This sharp decline...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- RPG Life Sciences bets big on API business, eyes GLP-1 entry by August-SeptemberRPG Life Sciences is prioritizing its API business for future growth, planning a significant acquisition to scale operations. The company a...
- Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Boom or bust? Analysts reveal what lies ahead for India Inc in FY27 amid Iran warIndian businesses brace for 2026-27 with geopolitical tensions and AI reshaping industries. While core sectors show stability, policy shift...
- Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?India's GLP-1 market is set for a massive boom. Following patent expiry, generic versions of semaglutide are launching at significantly low...
- The promise of EU-India FTA for Indian patients: A case for price regulationThe EU-India FTA promises cheaper drugs and medical devices, but India's regulatory framework may hinder patient benefits. Current pricing ...
- Biosimilars & innovation are Dr. Reddy’s growth pill: Generics to remain core business, says co-Chairman & MD GV PrasadDr Reddy's Laboratories is strategically shifting focus towards biosimilars and innovation. The company is increasing investment in biosimi...
- Dr Reddy's shares jump 5% despite 14% YoY fall in Q3 profit. Should you buy, sell or hold?Dr Reddy's shares: The company posted a 14% year-on-year decline in consolidated net profit to Rs 1,210 crore.
- Generic drug companies rework pricing to gain weight in India’s GLP-1 market as Novo Nordisk slashes Wegovy pricesIndian drugmakers are adjusting prices for weight-loss injections after Novo Nordisk cut prices for its drug Wegovy. This move is prompting...
- Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...
- Weight-loss drugs: Indian giants Dr Reddy’s to Macleods start preparing for Ozempic patent expiryIndian companies are gearing up to produce ingredients for generic weight-loss drugs. Novo Nordisk's patents are expiring soon. Dr Reddy's ...
- Buy, Sell or Hold: Nuvama initiates coverage on Eureka Forbes; Religare Broking positive on RECBrokerages stay bullish: Nuvama starts Eureka Forbes with Buy (20% upside), Motilal Oswal reaffirms Biocon Buy (13% upside), Religare Broki...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Which pharma companies will benefit from latest government policies? Sumit Gupta explainsThe Indian pharmaceutical sector is poised for growth, driven by government support for R&D and manufacturing. Policies promoting bulk drug...
Load More
